HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Risk-Adaptive Approaches Offer Safer, Effective Strategies for Early-Stage HER2+ Breast Cancer

March 5th 2022

The integration of HER2-targeted therapies into the treatment paradigm for patients with early-stage breast cancer, specifically the standard trastuzumab, has shifted focus away from whether patients should receive to how and when they should receive treatment with these agents.

Brain Metastases Are Now More Treatable in HER2+ Metastatic Breast Cancer

March 5th 2022

The treatment of patients with HER2-positive metastatic breast cancer can now be tailored based on the presence of active central nervous system disease, due to substantial advances made in the past few years into small molecule inhibitors and macromolecule biologics.

Addressing Cardiotoxicity in Breast Cancer Requires Multifaceted Approach

March 5th 2022

Clinicians with patients who are experiencing cardiotoxicity as a result of their breast cancer treatment should address the cardiotoxicity using a team-oriented approach based on guideline-directed therapies.

Dr. Tolaney on Potential of Trastuzumab Deruxtecan to Shift to First Line in HER2+ Breast Cancer

March 4th 2022

Sara M. Tolaney, MD, MPH, discusses the efficacy of trastuzumab deruxtecan in the second-line setting and its potential to move into the first-line treatment of HER2-positive breast cancer.

Hurvitz Reviews Pivotal Data From 2021, Previews Year Ahead in HER2+ Metastatic Breast Cancer

March 3rd 2022

Dr Hurvitz sheds light on shifts in practice patterns in HER2-positive breast cancer in light of data that emerged in 2021, remaining questions regarding treatment sequencing, the importance of updates to the National Comprehensive Cancer Network guidelines in metastatic HER2-positive breast cancer, and future directions to keep an eye on in 2022.

Key Data Illuminate New Directions in HER2-Positive Metastatic Breast Cancer Landscape

February 23rd 2022

An abundance of riches in the form of new data for HER2-targeted agents continues to drive progress for patients with metastatic breast cancer.

Patients With HER2+ Breast Cancer Who Achieve pCR With Neoadjuvant HER2-Targeted Therapy Have Better DFS, OS

February 9th 2022

Patients with HER2-positive, early-stage breast cancer who achieved a pathologic complete response after receiving HER2-targeted therapy experienced better outcomes in terms of disease-free survival and overall survival vs those who did not, according to data from a real-world study.

FLAMINGO-01 Trial Examining Adjuvant GLSI-100 in HER2+ Breast Cancer Approaches Initiation

February 2nd 2022

Significant progress has been made toward the initiation of the phase 3 FLAMINGO-01 trial, which will evaluate the combination of the immunotherapy GP2 with granulocyte macrophage colony stimulating factor in the adjuvant treatment of HER2/neu- and HLA-A*02–positive patients following surgery and trastuzumab-based therapy.

Breast Cancer Paradigm Pushes Forward With Novel Agents, Sequencing Strategies, and Dynamic Biomarkers

January 29th 2022

Aditya Bardia, MD, MPH, discusses key updates in HER2-positive, hormone receptor–positive, and triple-negative breast cancers, as well as the evolving clinical application of gene signature assays, liquid biopsies, and genotyping.

NCCN Guidelines Include Neratinib-Based Recommendations for HER2+ Breast Cancer

January 24th 2022

The National Comprehensive Cancer Network guidelines were updated for 2022 regarding the treatment of patients with breast cancer to include 2 new recommendations involving neratinib.

Dr. Cole on Next Steps With Tucatinib in HER2+ Breast Cancer

January 19th 2022

John Cole, MD, discusses the next steps with tucatinib in HER2-positive breast cancer.

NHS Scotland Accepts Trastuzumab Deruxtecan for Use in HER2+ Metastatic Breast Cancer

January 17th 2022

The Scottish Medicines Consortium has accepted fam-trastuzumab deruxtecan-nxki as a treatment option for adult patients with HER2-positive unresectable or metastatic breast cancer who have previously received 2 or more anti–HER2-based therapies.

FDA Grants Priority Review to Trastuzumab Deruxtecan for Select HER2+ Metastatic Breast Cancer

January 17th 2022

The FDA has granted priority review to the supplemental biologics license application of fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti–HER2-based regimen.1

Dr. Mortimer on the Potential Benefit of Tucatinib Plus ADCs in HER2+ Breast Cancer

January 14th 2022

Joanne Mortimer, MD, discusses the potential benefit of tucatinib plus antibody-drug conjugates in HER2-positive breast cancer.

Dr. Hurvitz on the Clinical Implications of the SUMMIT Trial in HER2-Mutated Breast Cancer

January 14th 2022

Sara A. Hurvitz, MD, discusses the clinical implications of the ongoing phase 2 SUMMIT trial in HER2-mutated breast cancer.

Dr. Tolaney on the Efficacy of Zanidatamab Plus Chemo in HER2+ Breast Cancer

January 14th 2022

Sara M. Tolaney, MD, MPH, sheds light on zanidatamab and the data reported with the agent in combination with chemotherapy for the treatment of patients with HER2-positive breast cancer.

Dr. Toppmeyer on Sequencing Therapy in HER2+ Breast Cancer

January 12th 2022

Deborah L. Toppmeyer, MD, discusses sequencing therapy in HER2-positive breast cancer.

Dr. Krop Discusses Progress Made in Metastatic HER2+ Breast Cancer

January 12th 2022

Ian E. Krop, MD, PhD, discusses progress made in 2021 in the management of HER2-positive breast cancer.

Dr. Brufsky on the Utility of Zanidatamab in HER2+ Breast Cancer

January 12th 2022

Adam M. Brufsky, MD, PhD, FACP, discusses the unique mechanism of action of zanidatamab and encouraging efficacy observed in patients with HER2-positive breast cancer.

Trastuzumab Deruxtecan Maintains PFS Benefit Across Subgroups in HER2+ Metastatic Breast Cancer

January 12th 2022

Sara Hurvitz, MD, discusses the findings from the subgroup analysis of the DESTINY-Breast03 trial, and future research directions for trastuzumab deruxtecan.